Table 3.
Clinical, demographic and treatment data of patients with ventricular dysfunction
| Variables | Functional recovery | p value | |
|---|---|---|---|
| Yes (n = 13) | No (n = 40) | ||
| Age (years) | 63.4 ± 12.3 | 56.2 ± 11.1 | 0.061 |
| Male, % (n) | 69.2 (9) | 77.5 (31) | 0.712 |
| SAH, % (n) | 38.5 (5) | 55.0 (22) | 0.473 |
| DM, % (n) | 15.4 (2) | 27.5 (11) | 0.480 |
| Dyslipidemia, % (n) | 84.6 (11) | 72.5 (29) | 0.480 |
| BMI (kg/m2) | 25.7 ± 3.5 | 26.8 ± 3.7 | 0.356 |
| WC (cm) | 92.4 ± 9.9 | 94.6 ± 9.8 | 0.483 |
| CPK (U/L) | 1.351 (841-4.167) | 5.587 (2.125-8.269) | 0.002 |
| CPK-MB (U/L) | 168 (80-273) | 579 (254-807) | < 0.001 |
| Primary angio, % (n) | 69.2 (9) | 70.0 (28) | 1.000 |
| Reperfusion, % (n) | 76.9 (10) | 87.5 (35) | 0.389 |
| ASA, % (n) | 100 (13) | 100 (40) | - |
| Clopidogrel, % (n) | 100 (13) | 100 (40) | - |
| ARB, % (n) | 7.7 (1) | 0 (0) | 0.245 |
| ACEI, % (n) | 84.6 (11) | 95.0 (38) | 0.249 |
| Beta-blocker, % (n) | 92.3 (12) | 95 (38) | 1.000 |
| Spironolactone, % (n) | 7.7 (1) | 27.5 (11) | 0.147 |
SAH: systemic arterial hypertension; DM: diabetes mellitus; BMI: body mass index; WC: waist circumference; CPK: creatine phosphokinase; CPK-MB: creatine phosphokinase-MB fraction; ASA: acetylsalicylic acid; ARB: angiotensin-II receptor blocker; ACEI: angiotensin-converting enzyme inhibitor Data expressed as mean ± SD or median (including 25th and 75th percentiles).